

Matthew Greenwood

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4151756/publications.pdf>

Version: 2024-02-01

58
papers

404
citations

933447

10
h-index

888059

17
g-index

58
all docs

58
docs citations

58
times ranked

606
citing authors

#	ARTICLE	IF	CITATIONS
1	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. <i>EJHaem</i> , 2022, 3, 129-138.	1.0	10
2	Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	1.3	2
3	The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. <i>Bone Marrow Transplantation</i> , 2022, 57, 982-989.	2.4	3
4	Sensitive Measurement of Minimal Residual Disease in Blood by High Annealing Temperature qPCR. <i>Journal of Molecular Diagnostics</i> , 2022, , .	2.8	1
5	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance. <i>Transplant Infectious Disease</i> , 2021, 23, e13548.	1.7	7
6	Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors. <i>Journal of Psychosocial Oncology</i> , 2021, 39, 534-552.	1.2	7
7	Poor mobilization of autologous CD34 ⁺ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminate potential. <i>British Journal of Haematology</i> , 2021, 193, 841-844.	2.5	6
8	Long-term Variability of Oscillatory Impedance in Stable Obstructive Airways Disease. <i>European Respiratory Journal</i> , 2021, 58, 2004318.	6.7	8
9	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
10	Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 1321-1323.	0.8	6
11	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	5.2	24
12	Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 798.e1-798.e10.	1.2	13
13	Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1022.e1-1022.e6.	1.2	11
14	Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13719.	1.7	3
15	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. <i>Blood Advances</i> , 2021, 5, 5574-5583.	5.2	6
16	Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index. <i>Blood</i> , 2021, 138, 3958-3958.	1.4	0
17	Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry. <i>Blood</i> , 2021, 138, 2929-2929.	1.4	0
18	Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021, 138, 4099-4099.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2021, 138, 882-882.	1.4	3
20	Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study. <i>Blood</i> , 2021, 138, 1234-1234.	1.4	7
21	SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab502.	0.9	2
22	Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival. <i>Leukemia and Lymphoma</i> , 2020, 61, 831-839.	1.3	5
23	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2252-2261.	2.0	6
24	Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. <i>Blood Advances</i> , 2020, 4, 4147-4150.	5.2	31
25	Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes—a short report from two Sydney centres. <i>British Journal of Haematology</i> , 2020, 191, e58-e60.	2.5	1
26	Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement. <i>Internal Medicine Journal</i> , 2020, 50, 774-775.	0.8	3
27	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1868-1875.	2.0	8
28	Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1460-1463.	2.4	3
29	<scp>Epstein-Barr</scp> virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. <i>Reviews in Medical Virology</i> , 2020, 30, e2108.	8.3	13
30	An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
31	A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up. <i>Blood</i> , 2020, 136, 51-52.	1.4	0
32	Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
33	Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
34	Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
35	Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2019, 134, 1300-1300.	1.4	5
36	An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era. <i>Blood</i> , 2019, 134, 5719-5719.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Lymphoma cellâ€œofâ€œorigin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. <i>British Journal of Haematology</i> , 2018, 181, 272-275.	2.5	8
38	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. <i>Internal Medicine Journal</i> , 2018, 48, 276-285.	0.8	13
39	1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data. <i>Open Forum Infectious Diseases</i> , 2018, 5, S342-S342.	0.9	1
40	Expression of Intracellular Reactive Oxygen Species in Hematopoietic Stem Cells Correlates with Time to Neutrophil and Platelet Engraftment in Patients Undergoing Autologous Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1997-2002.	2.0	5
41	High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL). <i>Blood</i> , 2018, 132, 2831-2831.	1.4	2
42	DNA Damage in Haemopoietic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation. <i>Blood</i> , 2018, 132, 4622-4622.	1.4	0
43	Nutritional issues and body weight in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia. <i>Supportive Care in Cancer</i> , 2017, 25, 137-144.	2.2	12
44	Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3414-3419.	3.0	43
45	Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic Tâ€œcell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 914-917.	1.7	50
46	Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia. <i>Cancer Medicine</i> , 2016, 5, 3606-3614.	2.8	9
47	Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study. <i>Blood</i> , 2015, 126, 2108-2108.	1.4	0
48	Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders. <i>Blood</i> , 2015, 126, 5038-5038.	1.4	0
49	Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2656-2656.	1.4	0
50	Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. <i>Biomarker Research</i> , 2014, 2, 16.	6.8	26
51	Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL). <i>Blood</i> , 2014, 124, 1742-1742.	1.4	2
52	Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia â€œ a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse. <i>Blood</i> , 2014, 124, 1927-1927.	1.4	2
53	Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8563-8563.	1.6	1
54	Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients. <i>Blood</i> , 2012, 120, 3612-3612.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06â€™0002 Study Update. <i>Blood</i> , 2012, 120, 3641-3641.	1.4	1
56	Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2011, 118, 591-591.	1.4	1
57	High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study. <i>Blood</i> , 2011, 118, 2624-2624.	1.4	0
58	Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy. <i>Blood</i> , 2010, 116, 114-114.	1.4	18